Solventum Corp SOLV
Solventum Corporation ("Solventum," "we," "our," "us," or the "Company"), is a leading global healthcare company developing, manufacturing, and commercializing a broad portfolio of solutions that leverages deep material science, data science, and digital capabilities to address critical customer and patient needs. We constantly seek to enable the improvement of standards of care and move healthcare forward with innovation powered by insights, clinical intelligence, technology, and manufacturing expertise. Our 70+ year history of discovering and innovating advanced solutions has helped us solve our customers' toughest challenges.
Our solutions are relied on every day within the global healthcare industry to deliver higher-quality patient care, more efficient processes and workflows, and improved standards of safety and accuracy. Additionally, our products and services are present along a patient's journey through prevention, diagnosis, treatment, and recovery.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $8.32B | $8.25B | $8.20B | $8.13B | — |
| Gross profit | $4.45B | $4.59B | $4.69B | $4.70B | — |
| R&D | $739.0M | $775.0M | $758.0M | $767.0M | — |
| SG&A | $3.08B | $2.78B | $2.30B | $2.23B | — |
| Operating income | $2.18B | $1.04B | $1.69B | $1.69B | — |
| Pre-tax income | $1.71B | $605.0M | $1.67B | $1.69B | — |
| Income tax | $157.0M | $127.0M | $321.0M | $349.0M | — |
| Net income | $1.56B | $479.0M | $1.35B | $1.34B | — |
| EPS, basic | 8.94 | 2.77 | 7.79 | 7.78 | — |
| EPS, diluted | 8.88 | 2.76 | 7.79 | 7.78 | — |
| Shares, diluted (wtd. avg.) | $175.3M | $173.7M | $172.7M | $172.7M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $878.0M | $762.0M | $194.0M | $61.0M | $91.0M |
| Receivables | $1.03B | $1.04B | $1.31B | — | — |
| Inventory | $1.07B | $965.0M | $857.0M | — | — |
| Total current assets | $3.86B | $3.25B | $2.52B | — | — |
| Property, plant and equipment | $1.33B | $1.62B | $1.46B | — | — |
| Goodwill | $5.70B | $6.38B | $6.54B | $6.43B | — |
| Other intangibles | $2.59B | $2.54B | $2.90B | — | — |
| Total assets | $14.29B | $14.46B | $13.94B | — | — |
| Accounts payable | $687.0M | $618.0M | $477.0M | — | — |
| Short-term debt | $0 | $200.0M | $0 | — | — |
| Total current liabilities | $3.14B | $2.70B | $1.73B | — | — |
| Long-term debt | $5.04B | $7.81B | $0 | — | — |
| Total liabilities | $9.24B | $11.50B | $2.28B | — | — |
| Retained earnings | $1.80B | $242.0M | $0 | — | — |
| Total equity | $5.05B | $2.96B | $11.67B | $11.74B | $12.06B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | $369.0M | $1.19B | $1.92B | $1.68B | — |
| Depreciation and amortisation | $489.0M | $555.0M | $561.0M | $578.0M | — |
| Stock-based compensation | $161.0M | $112.0M | $39.0M | $37.0M | — |
| Capital expenditure | $379.0M | $380.0M | $290.0M | $251.0M | — |
| Investing cash flow | $2.80B | -$380.0M | -$230.0M | -$253.0M | — |
| Financing cash flow | -$3.06B | -$240.0M | -$1.55B | -$1.46B | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001964738-26-000007.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |